- Home
- RGT vs AGEN Comparison
RGT vs AGEN Comparison
Compare RGT & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGT
- AGEN
- Stock Information
- Founded
- RGT 1986
- AGEN 1994
- Country
- RGT United States
- AGEN United States
- Employees
- RGT N/A
- AGEN N/A
- Industry
- RGT Trusts Except Educational Religious and Charitable
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RGT Finance
- AGEN Health Care
- Exchange
- RGT Nasdaq
- AGEN Nasdaq
- Market Cap
- RGT 80.2M
- AGEN 87.7M
- IPO Year
- RGT N/A
- AGEN 2000
- Fundamental
- Price
- RGT $11.93
- AGEN $5.36
- Analyst Decision
- RGT
- AGEN Strong Buy
- Analyst Count
- RGT 0
- AGEN 3
- Target Price
- RGT N/A
- AGEN $16.33
- AVG Volume (30 Days)
- RGT 22.4K
- AGEN 1.3M
- Earning Date
- RGT 01-01-0001
- AGEN 08-11-2025
- Dividend Yield
- RGT 1.43%
- AGEN N/A
- EPS Growth
- RGT N/A
- AGEN N/A
- EPS
- RGT 0.92
- AGEN N/A
- Revenue
- RGT N/A
- AGEN $99,524,000.00
- Revenue This Year
- RGT N/A
- AGEN $25.31
- Revenue Next Year
- RGT N/A
- AGEN N/A
- P/E Ratio
- RGT $11.42
- AGEN N/A
- Revenue Growth
- RGT N/A
- AGEN N/A
- 52 Week Low
- RGT $7.84
- AGEN $1.38
- 52 Week High
- RGT $11.08
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- RGT 38.16
- AGEN 45.74
- Support Level
- RGT $12.18
- AGEN $5.76
- Resistance Level
- RGT $12.39
- AGEN $6.58
- Average True Range (ATR)
- RGT 0.11
- AGEN 0.49
- MACD
- RGT -0.07
- AGEN -0.15
- Stochastic Oscillator
- RGT 7.44
- AGEN 1.20
About RGT Royce Global Value Trust Inc.
Royce Global Value Trust Inc is a diversified closed-end investment company. The fund spreads its investments across diversified sectors such as information technology, consumer discretionary, health care, materials, consumer staples, and energy. Geographically, it has presence in the region of the United Kingdom, Japan, the United States, Canada, France, Hong Kong, and Germany.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).